Emerging Landscape of Targeted Protein Degradation Therapeutics, 2023 Research Report - Rapid Technology Advances Bolster a Robust Therapeutic Pipeline

Dublin, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The "Emerging Landscape of Targeted Protein Degradation Therapeutics" report has been added to ResearchAndMarkets.com's offering.

This research report provides an in-depth analysis of the emerging field of targeted protein degradation (TPD). TPD strategies offer a revolutionary approach to treating diseases that were previously untreatable using conventional methods. By selectively targeting disease-causing proteins, TPD minimizes the risk of side effects.

The report explores different categories of protein degraders, both extracellular and intracellular, and their respective research and development focuses. It assesses the suitability of various degraders for different diseases, identifies key players in the field, and discusses their clinical applications.

One significant finding is that approximately 80% of a cell's proteome cannot be effectively targeted using traditional approaches like small molecule inhibitors, antisense oligonucleotides (ASO), or monoclonal antibodies. This limitation has driven the rapid advancement of TPD over the last two decades, with PROTACs emerging as the most widely researched protein degraders.

The report also distinguishes between intracellular and extracellular protein degraders. Intracellular degraders utilize the ubiquitin-proteasomal degradation pathway to target intracellular proteins. However, around 40% of genes encoding extracellular and membrane-associated proteins cannot be accessed by intracellular protein degraders. This has led to the development of extracellular protein degradation strategies.

The growth of targeted protein degradation technology is significantly influenced by increased funding from both the private and public sectors. The report includes an analysis of funding trends in the TPD space, highlighting the importance of financial support in driving innovation in this field.

Questions that this report seeks to answer include:

  • What are the key drivers or challenges for TPD development?
  • How do the private funding and partnership landscapes look for TPD?
  • Who are the key industry participants developing targeted protein degraders?
  • What are the R&D trends emerging across TPD that could further shape the development of protein degraders?

Key Topics Covered:

1 Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative
  • The Impact of the Top 3 Strategic Imperatives on the Targeted Protein Degradation Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine
  • Research Methodology
  • Introduction

2 Growth Opportunity Analysis

  • Growth Drivers
  • Growth Driver Analysis
  • Growth Restraints
  • Growth Restraints Analysis
  • Scope of Analysis
  • Segmentation
  • The Need for Targeted Protein Degraders

3 R&D and Innovation Ecosystem

  • TPD - Evolution and Clinical aspect
  • Intracellular Targeted Protein Degraders in Clinical Development
  • Intracellular Targeted Protein Degraders - PROTACs
  • Emerging Intracellular Targeted Protein Degraders
  • Innovation Spotlight - Intracellular Protein Degradation
  • Development of Extracellular Protein Degradation Therapeutics
  • Challenges for Extracellular Protein Degrader Development
  • Extracellular Protein Degradation Approaches
  • Emerging Classes of Extracellular Protein Degraders
  • Innovation Spotlight - Extracellular Protein Degradation
  • Key Differences Between Extracellular and Intracellular Protein Targeting
  • Targeted Protein Degradation Technology Snapshot

4 R&D Focus and Application Landscape

  • R&D Innovation Trends
  • Protein Degraders in Healthcare and Beyond
  • Protein Degraders across Different Disease Areas
  • Key Players and Therapeutics Areas of Focus
  • Protein Degraders Innovation Landscape

5 Market Dynamics

  • Public and Private Funding for TPD Therapy Development
  • Partnership Landscape of Biopharma Companies in TPD Therapeutics Development
  • TPD Companies' Partnerships for Developing TPD Therapeutics

6 Growth Opportunity Universe

  • Growth Opportunity 1: Efficient and Tissue-specific Degrader Delivery
  • Growth Opportunity 2: Novel E3 Ligases Discovery and Design
  • Growth Opportunity 3: Advanced PROTACs Development
  • Growth Opportunity 4: Research and Product Development Partnerships to Develop Next-gen TPD Therapeutics

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/if1oqw

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data